Increased Body Mass Index Is Associated With A Nondilutional Reduction in Antimüllerian Hormone
- PMID: 32756952
- PMCID: PMC7448935
- DOI: 10.1210/clinem/dgaa436
Increased Body Mass Index Is Associated With A Nondilutional Reduction in Antimüllerian Hormone
Abstract
Context: Controversy exists regarding if and how body mass index (BMI) impacts antimüllerian hormone (AMH) in women with and without polycystic ovary syndrome (PCOS). Understanding the BMI-AMH relationship has critical implications for clinical interpretation of laboratory values and could illuminate underlying ovarian physiology.
Objective: To test the hypotheses that (1) BMI is associated with reduced AMH in PCOS and ovulatory controls (OVAs) and (2) the reduction in AMH is not accounted for by dilutional effects.
Design/setting: Multicenter cohort.
Participants: Women aged 25 to 40 years from 2 clinical populations: 640 with PCOS, 921 women as OVAs.
Main outcome measures: Ovarian reserve indices: AMH, antral follicle count (AFC), and AMH to AFC ratio (AMH/AFC) as a marker of per-follicle AMH production.
Results: In both cohorts, increasing BMI and waist circumference were associated with reductions in AMH and AMH/AFC, after adjusting for age, race, smoking, and site in multivariate regression models. Increasing BMI was associated with reduced AFC in PCOS but not OVAs. Body surface area (BSA), which unlike BMI is strongly proportional to plasma volume, was added to investigate a potential dilutive effect of body size on AMH concentrations. After controlling for BSA, BMI retained independent associations with AMH in both cohorts; BSA no longer associated with AMH.
Conclusions: In an adjusted analysis, BMI, but not BSA, was associated with reduced AMH; these data do not support a role for hemodilution in mediating the relationship between increased body size and reduced AMH. Decreased AMH production by the follicle unit may be responsible for reduced AMH with increasing BMI.
Keywords: antimüllerian hormone; antral follicle count; obesity; ovarian reserve; polycystic ovary syndrome.
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
References
-
- Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2012;98(6):1407-1415. - PubMed
-
- Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30(5): 465-493. - PubMed
-
- Greenwood EA, Cedars MI, Santoro N, et al. ; National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network . Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility. Fertil Steril. 2017;108(6):1070-1077. - PubMed
-
- Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum Reprod Update. 2014;20(3):370-385. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
